Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice.

Journal:
The Journal of infectious diseases, Volume: 221, Issue: 7
Published:
March 16, 2020
PMID:
31605489
Authors:
Noton K Dutta NK, Natalie Bruiners N, Matthew D Zimmerman MD, Shumin Tan S, VĂ©ronique Dartois V, Maria L Gennaro ML, Petros C Karakousis PC
Abstract:

Tuberculosis (TB) treatment is lengthy and complicated and patients often develop chronic lung disease. Recent attention has focused on host-directed therapies aimed at optimizing immune responses to Mycobacterium tuberculosis (Mtb), as adjunctive treatment given with antitubercular drugs. In addition to their cholesterol-lowering properties, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have broad anti-inflammatory and immunomodulatory activities.